Data from AMPLE† presented at EULAR 2013, the Annual Congress of the European League Against Rheumatism, demonstrate comparable efficacy and similar safety profiles between subcutaneous abatacept (ABA) and adalimumab (ADA). AMPLE, the first two-year head-to-head biologics trial, was comprised of 646 biologic-naïve patients with active rheumatoid arthritis (RA) equally randomised to either ABA or ADA, with a stable dose of methotrexate (MTX). 79.2% (252 of 318) ABA patients and 74.7% (245 of 328) ADA patients completed the trial. RA is a chronic autoimmune disease that principally attacks flexible joints.
† AMPLE, Abatacept Versus Adalimumab Comparison in Biologic-Naive RA Subjects with Background Methotrexate
‡DMARDs, disease modifying anti-rheumatic drugs
* ACR (American College of Rheumatology) criteria measures improvement in tender or swollen joint
counts and improvement in three of the following five parameters: acute phase reactant (such as
sedimentation rate), patient assessment, physician assessment, pain scale and disability/functional
questionnaire. ACR20 refers to a 20% improvement in tender/swollen joint counts, as well as in three
of the five criteria.
1. Schiff M et al., Head-to-head comparison of subcutaneous abatacept versus adalimumab on
background methotrexate in RA: two year results from the AMPLE study [abstract]. EULAR
Annual European Congress of Rheumatology; 12-15 June 2013; Madrid, Spain. Abstract nr.
2. Chronic Diseases and Health Promotion: Chronic Rheumatic Conditions, World Health
Organization. Available from: http://www.who.int/chp/topics/rheumatic/en/ Last accessed: May